Inflammasome components as new therapeutic targets in inflammatory disease
Nature Reviews Immunology · 2025-01 · 25 (1) · 22-41
DOI: 10.1038/s41577-024-01075-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Immunology, online erschienen am 09.09.2024. Verfasst von Rebecca C Coll und 1 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. R.Coll@qub.ac.uk. Hauptthemen laut MEDLINE: Inflammasomes, Inflammation, NLR Family, Pyrin Domain-Containing 3 Protein, Signal Transduction. Die Arbeit wurde bisher 164-mal zitiert (Crossref) und nennt 212 Literaturangaben.
Abstract (Originalsprache)
Inflammation drives pathology in many human diseases for which there are no disease-modifying drugs. Inflammasomes are signalling platforms that can induce pathological inflammation and tissue damage, having potential as an exciting new class of drug targets. Small-molecule inhibitors of the NLRP3 inflammasome that are now in clinical trials have demonstrated proof of concept that inflammasomes are druggable, and so drug development programmes are now focusing on other key inflammasome molecules. In this Review, we describe the potential of inflammasome components as candidate drug targets and the novel inflammasome inhibitors that are being developed. We discuss how the signalling biology of inflammasomes offers mechanistic insights for therapeutic targeting. We also discuss the major scientific and technical challenges associated with drugging these molecules during preclinical development and clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. R.Coll@qub.ac.uk.
- Institute for Molecular Bioscience (IMB), The University of Queensland, St Lucia, Queensland, Australia. K.Schroder@imb.uq.edu.au.
Zitieren
APA
Coll, R. C., & Schroder, K. (2025). Inflammasome components as new therapeutic targets in inflammatory disease. Nature Reviews Immunology, 25(1), 22-41. https://doi.org/10.1038/s41577-024-01075-9
Vancouver
Coll RC, Schroder K. Inflammasome components as new therapeutic targets in inflammatory disease. Nature Reviews Immunology. 2025;25(1):22-41. doi:10.1038/s41577-024-01075-9
BibTeX
@article{Coll2025,
author = {Coll, Rebecca C and Schroder, Kate},
title = {Inflammasome components as new therapeutic targets in inflammatory disease},
journal = {Nature Reviews Immunology},
year = {2025},
volume = {25},
number = {1},
pages = {22--41},
doi = {10.1038/s41577-024-01075-9}
}
EUVIMED